Miliary Adenocarcinoma of the Lung Responds to Gefitinib and Afatinib

J Thorac Oncol. 2018 Jun;13(6):e95-e97. doi: 10.1016/j.jtho.2018.01.018.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Afatinib / pharmacology
  • Afatinib / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Gefitinib / pharmacology
  • Gefitinib / therapeutic use*
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged

Substances

  • Antineoplastic Agents
  • Afatinib
  • Gefitinib